NEW YORK (GenomeWeb) – N-of-One today said that it will provide OncoDNA with clinical interpretation services for its next-generation sequencing and other molecular tests for patients throughout Europe.

Belgium-based OncoDNA provides personalized medicine testing services for cancer patients. One of its tools is the OncoDEEP Clinical Plus test, which is an adapted version of the 400-gene Ion comprehensive cancer panel on the Ion Proton. It also offers a more focused targeted sequencing test, OncoDEEP Dx, using the 48-gene Ion AmpliSeq cancer panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.